RE:RE:RE:GamechangerWell said and very true.
As I have mentioned before, the better quality the partner, the higher likelihood of success for us shareholders.
AbbVie/Allergan seem to be the highest rated organization from both size/magnitude and market presence point of view to date out of all those you listed.
While I remain hopeful they announce a launch sooner than later, I reiterate the most logical time they would launch new products with 1067 is the 2 year anniversary of their last Skinmedica product update launch which will be this upcoming January. If one looks at their historical updates, that seems to be the cycle.
If they remain on track, which all current indications reveal, then our pay day on this part of the business pipeline will commence then, with a potential build up in share price starting the moment we start to see clues "in the system", meaning product name trademark registrations, or other publicly available reference points. My guess is the bread crumbs will be there as early as this fall.
In the meantime we have the launch of 1326 to dream about and any evidence that this has legs will give us a much needed inspirational uplift. If some institution or equity players come to the table with real dollar commitments to the company or its new subsidiary then that to me says someone external has put their money into the plan and probably has a higher level of certainty that success is achievable than any of us can understand with the limited information set we have as shareholders.
So if that scenario plays out